MBC Pharma Inc. Awarded a SBIR Phase II Grant to Further Develop a Novel Bone-Targeted Combination Treatment for Osteosarcoma

MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $2M Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to build upon the success of the Phase I grant—demonstration of in vivo efficacy in model systems of osteosarcoma. The new work will focus on optimizing the method of use and testing the drug combination in spontaneous canine osteosarcoma.

“This grant will let us take our bone-targeting platform to the next level. We are leveraging targeting as a way to amplify the benefits of combination therapy. This should increase specificity while decreasing the dose amount, and decrease side-effects. Successful completion of this grant work would provide us with proof-of-concept in spontaneous disease and position us to push for human clinical testing. And there is real need for new drugs for patients with osteosarcoma,” said Dr. Shawn Zinnen, CEO and the Principal Investigator on the SBIR grant.

“We would like to acknowledge the support of NIH SBIR program in the development of MBC technology. We are excited to further develop our 2nd-generation approach to treating cancer induced bone disease towards providing new treatment for osteosarcoma, so important for children and adults patients,” added Dr. Alexander Karpeisky, President, CSO and coinvestigator on the grant.

About MBC Pharma

MBC Pharma is a privately held pharmaceutical company developing bone targeted therapeutics for serious diseases and conditions of bone with an oncology and anti-infectives focus.

For information on MBC Pharma please contact Dr. Alexander Karpeisky at 720-859-4041 or Dr. Shawn Zinnen at 720-859-4040


Go Back